-
Event
20 November 2026, The Hotel Brussels & Online
Advancing Collaboration, Skills and Person-Centred Care through INTERACT-EUROPE 100
Bringing together Europe’s oncology community at a pivotal moment, this conference will showcase the achievements of INTERACT-EUROPE 100 while charting the next phase of inter-speciality cancer training across Europe. It offers a unique opportunity to transform the programme’s success into lasting, system-wide adoption, ultimately advancing cancer care and outcomes for people across Europe.
Read more
-
Event
20 November 2026, The Hotel Brussels
Quality of life is a key priority for anyone affected by cancer, but it remains insufficiently addressed in cancer research, care and policy.
On 20 November, the Quality of Life and Cancer Policy Forum will explore lessons from nine innovative projects and how cancer systems can be redesigned towards patient-centred care.
Taking place a day after the European Cancer Summit 2026 – and at the same venue – this high-level, implementation-focused event will bring together patient representatives, researchers, healthcare professionals, health system managers and policymakers to learn about the latest EU-supported initiatives and get empowered to drive meaningful change.
This event will feature:
- the EUonQoL project, developing a patient-centred unified tool for the assessment of quality of life among cancer patients and survivors – serving as its final policy event
- the projects of the Quality of Life - Patient-Centred Care Cluster of the EU Mission on Cancer – serving as their multi-stakeholder meeting
Read more
-
Event
18 - 19 November 2026, Brussels & online
Strengthening Cancer Care: Securing a Healthy, Equitable, Resilient and Competitive Europe
Amid political instability, economic pressure, and the risk of escalating conflict, discussions around Europe’s next multiannual budget are intensifying in Brussels and in capitals across the EU.
In this environment, addressing the growing burden of cancer is essential. This unrelenting disease is not only a public health priority, but a strategic investment in Europe’s resilience, social cohesion and long‑term competitiveness.
As Europe defines its political priorities for the decade ahead, health and cancer must be embedded at the heart of future investments. At this critical moment, the cancer community must champion a vision for a resilient, equitable and innovative Europe.
The European Cancer Summit 2026 will take place in Brussels & online on 18-19 November, followed by EU-funded project events on 20 November.
Read more
-
Event
13 - 14 October 2026, The Hoxton
The SANGUINE Project Showcase Event:
Advancing the HemaChip from Research to Impact
Every year, around 300,000 people across the EU are diagnosed with a haematological malignancy, including leukaemia, lymphoma and multiple myeloma.
Yet diagnosing blood cancer remains a complex challenge. With more than 100 different types and subtypes, many diseases share overlapping clinical and laboratory features, requiring multiple tests to reach an accurate diagnosis.
Read more
-
Event
23 September 2026, Online
Men still hit obstacles at every stage of cancer care – from prevention and early detection through treatment and life afterwards. Many are raised to tough things out and avoid asking for help. Add in the embarrassment of discussing intimate symptoms, a health system that's often difficult to figure out, and care that's scattered across different places – and it's no surprise many men struggle to look after themselves or get the support they need.
Unequal access means some men miss out on the latest therapies, and once treatment is over, their physical, emotional and social needs are often left unmet.
Read more
-
news
06 August 2026
The European Cancer Organisation (ECO) has submitted its response to the European Commission’s public consultation on the proposed EU Biotech Act, welcoming its potential to strengthen European innovation and access for patients, while proposing needed additional measures.
The Biotech Act represents an important opportunity to create a European environment in which biotechnology research and innovation can flourish. For cancer care, this could accelerate progress in areas including advanced therapies, precision medicine, radiopharmaceuticals, and AI-enabled diagnostics, helping innovative treatments reach patients more quickly and equitably.
Following the publication of the European Biotech Act proposal on 16 December 2025, the European Commission invited stakeholders to provide feedback.
ECO’s response focuses on three priorities: improving the regulatory environment for clinical trials in Europe; strengthening access to Advanced Therapy Medicinal Products (ATMPs); and ensuring greater policy attention is given to health and oncology workforce needs.
Read more
-
Publication
August 2026
The report is the latest output from the EU-CIP (European Cancer Information Portal) project. It is entitled Building a Trusted and Accessible Cancer Information Ecosystem in Europe and brings together the findings of the April 2026 EU-CIP Stakeholder Co-Creation Forum, organised by the European Cancer Organisation with the support of project partners.
Read more
-
community-voices
July 2026
By Dr Wendy McInally - President, European Oncology Nursing Society
Some of the most important moments in cancer care never appear in a patient’s medical record. They are the conversations that ease anxiety, the explanations that build understanding and the reassurance that helps someone face what comes next. The work of cancer nurses makes these moments possible. Across Europe, however, the time they require is becoming harder to protect.
Read more
-
news
28 July 2026
The European Cancer Organisation (ECO) is inviting the cancer community to contribute evidence on the economic and societal value of cancer control interventions across Europe.
Cancer results in massive economic losses across Europe, driven by healthcare costs, lost productivity, labour market disruption, and premature mortality. Beyond saving lives, cancer care generates crucial value for European economies and societies. As discussions on the future of EU cancer policy continue, bringing this evidence to the forefront is more important than ever.
As part of the Reach Higher for Cancer Care campaign, ECO is developing an investment case for cancer policy action. Contributions to this call for evidence will inform a dedicated report highlighting the economic and societal returns of investing in cancer control, which will be launched at the 2026 European Cancer Summit.
Read more
